22:57 , Jul 19, 2018 |  BC Extra  |  Preclinical News

Inhibiting EIF2AK1 could help treat sickle cell disease

Researchers from Children’s Hospital of Philadelphia and University of Pennsylvania showed that inhibiting EIF2AK1 to increase fetal hemoglobin could help treat sickle cell disease. As genetic diseases such as SCD and some thalassemias affect patients only...
18:52 , Jul 12, 2018 |  BC Innovations  |  Product R&D

All-in-one viruses

Having taken its lead oncolytic virus into the clinic, PsiOxus Therapeutics Ltd. is building an immuno-oncology platform that uses engineered versions of the vector to selectively target multiple genes at a time to tumor cells...
03:04 , Jun 30, 2018 |  BioCentury  |  Finance

Eyes on launches

The annual summer slowdown isn’t restricted to just the stock market this year, as the clinical catalyst calendar also appears to be on holiday in 3Q18. Buysiders are therefore turning their attention to a spate of...
14:45 , Jun 29, 2018 |  BC Week In Review  |  Clinical News

Global Blood reports Phase III sickle cell data that could support accelerated approval of voxelotor

Global Blood Therapeutics Inc. (NASDAQ:GBT) reported data from Part A of the Phase III HOPE trial that it believes could support accelerated approval of voxelotor (formerly GBT440) to treat sickle cell disease. The company said voxelotor...
22:24 , Jun 27, 2018 |  BC Extra  |  Clinical News

Global Blood rises on 12-week sickle cell data

Global Blood Therapeutics Inc. (NASDAQ:GBT) gained $6.05 (16%) to $44.75 Wednesday after reporting data from Part A of the Phase III HOPE study that it believes could support accelerated approval of voxelotor (formerly GBT440) to...
18:26 , Jun 22, 2018 |  BC Week In Review  |  Clinical News

bluebird on track to submit MAA to EMA for LentiGlobin

bluebird bio Inc. (NASDAQ:BLUE) said it is on track to submit an MAA to EMA next half for its LentiGlobin BB305 to treat beta-thalassemia and reported additional data from three studies of the gene therapy....
15:33 , Jun 22, 2018 |  BC Week In Review  |  Clinical News

Global Blood's voxelotor shows lower response rate in 24-week sickle cell readout

Global Blood Therapeutics Inc. (NASDAQ:GBT) reported updated Phase IIa data in sickle cell disease patients showing that voxelotor (formerly GBT440) led to a lower hemoglobin response rate than previously reported data had shown. At the European...
23:28 , Jun 15, 2018 |  BC Extra  |  Clinical News

bluebird on track to submit MAA to EMA for LentiGlobin

bluebird bio Inc. (NASDAQ:BLUE) said it is on track to submit an MAA to EMA next half for its LentiGlobin BB305 to treat beta-thalassemia and reported additional data from three studies of the gene therapy....
20:47 , Jun 15, 2018 |  BC Extra  |  Clinical News

Global Blood down on 24-week sickle cell readout

Global Blood Therapeutics Inc. (NASDAQ:GBT) lost $7 (15%) to $40.05 on Friday after updated Phase IIa data in sickle cell disease patients showed that voxelotor (formerly GBT440) led to a lower hemoglobin response rate than...
19:51 , Apr 27, 2018 |  BC Week In Review  |  Clinical News

Alexion's long-acting C5 inhibitor meets in Phase III switch trial

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) reported in its 1Q18 earnings release on April 26 that ALXN1210, its long-acting formulation of Soliris eculizumab, met the primary and four key secondary endpoints in the the Phase III ALXN1210-PNH-302...